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 Abstract 
 Kallikrein 14 (KLK14) has been proposed as a useful prog-
nostic marker in prostate cancer, with expression reported to 
be associated with tumour characteristics such as higher stage 
and Gleason score. KLK14 tumour expression has also shown 
the potential to predict prostate cancer patients at risk of dis-
ease recurrence after radical prostatectomy. The  KLKs are a 
remarkably hormone-responsive family of genes, although 
detailed studies of androgen regulation of KLK14 in prostate 
cancer have not been undertaken to date. Using  in vitro stud-
ies, we have demonstrated that unlike many other prostatic 
 KLK genes that are strictly androgen responsive,  KLK14 is 
more broadly expressed and inversely androgen regulated in 
prostate cancer cells. Given these results and evidence that 
KLK14 may play a role in prostate cancer prognosis, we also 
investigated whether common genetic variants in the  KLK14 
locus are associated with risk and/or aggressiveness of pros-
tate cancer in approximately 1200 prostate cancer cases and 
1300 male controls. Of 41 single nucleotide polymorphisms 
assessed, three were associated with higher Gleason score 
( ≥ 7): rs17728459 and rs4802765, both located upstream of 
 KLK14 , and rs35287116, which encodes a p.Gln33Arg sub-
stitution in the KLK14 signal peptide region. Our fi ndings 
provide further support for KLK14 as a marker of prognosis 
in prostate cancer. 
 Keywords:  androgen regulation;  Gleason score;  
kallikreins;  KLK14;  prostate cancer;  single nucleotide 
polymorphisms (SNPs). 
 Introduction 
 The kallikrein (KLK) family of serine peptidases are a promi-
nent group of prostatic proteins. In the normal prostate, 
KLKs are secreted into seminal plasma where they act in an 
enzyme cascade to degrade the seminal clot (Veveris -Lowe 
et al., 2007 ; Emami and Diamandis , 2008 ). In prostate can-
cer, KLKs are over-expressed and aberrantly secreted into the 
tumour microenvironment and, ultimately, the bloodstream. 
This makes the KLKs not only potential functional mediators 
of tumour progression but also a rich source of biomarkers. 
 Like several other KLKs, KLK14 has been shown to be 
aberrantly expressed in hormone-dependent cancers of the 
breast, ovary and prostate and has been proposed as a use-
ful prognostic marker (Mavridis and Scorilas , 2010 ). There 
is some evidence to support a role for KLK14 in prostate 
cancer risk and aggressiveness.  KLK14 was found to be 
over-expressed in prostate tumours vs. matched normal tissue 
(Yousef et al. , 2003b ). Although Rabien et al.  (2008) reported 
that KLK14 mRNA and protein were not differentially 
expressed between prostate cancer and normal tissue, this 
same study showed that KLK14 tumour protein expression 
was associated with tumour pathological characteristics such 
as higher stage and higher Gleason score, and had potential to 
predict prostate cancer patients at risk of disease recurrence 
[as defi ned by prostate-specifi c antigen (PSA) relapse] after 
radical prostatectomy. KLK14 tumour protein expression was 
also reported to be associated with higher Gleason score by 
Yousef et al.  (2003b) , and KLK14 has been shown to be ele-
vated in serum from prostate cancer patients when compared 
with healthy males (Borgono et al. , 2007 ). Given the recogni-
tion that genetic variation can be associated with altered pro-
tein expression and prostate cancer risk, as exemplifi ed by 
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the discovery that a single nucleotide polymorphism (SNP) in 
 KLK3 is associated with PSA levels and prostate cancer risk 
(Eeles et al. , 2008 ; Kote -Jarai et al., 2011 ; Parikh et al. , 2011 ), 
altogether these results indicate a need to further investigate 
 KLK14 , and the SNPs within this gene, as a potential prostate 
cancer biomarker. 
 Androgens are critically involved in prostate cancer pro-
gression, with androgen deprivation therapy being a key 
therapeutic regimen for advanced disease. The KLKs are a 
remarkably hormone-responsive family of genes, especially 
 KLK2 and  KLK3 , which are considered to be prototypical 
androgen-regulated genes (Lawrence et al. , 2010 ), and are 
only expressed in androgen-responsive prostate epithelial 
cells. Several studies have shown that  KLK14 mRNA expres-
sion in breast and ovarian cancer cell lines is stimulated by 
steroid hormones, including androgens, oestrogens, and pro-
gestins, although these effects are more subtle at the protein 
level (Borgono et al. , 2003 ; Yousef et al. , 2003a ; Paliouras 
and Diamandis , 2007, 2008b ; Shaw and Diamandis , 2008 ). 
In prostate cancer cells, KLK14 is ubiquitously expressed at 
low levels, and is not correlated with the androgen receptor 
(AR) status of cell lines (Lawrence et al. , 2010 ); however, 
detailed studies of androgen regulation of KLK14 have not 
been undertaken to date. In this study, we aimed to examine 
androgen regulation of KLK14 expression in prostate cancer 
cells with a goal of better understanding the reported associa-
tion with prostate cancer progression (Yousef et al. , 2003b ; 
Rabien et al. , 2008 ). 
 In parallel, we investigated the concept that common 
genetic variation (SNPs) in the  KLK14 gene may affect 
KLK14 expression and hence alter prostate cancer risk and/or 
the likelihood of more aggressive prostate tumours in carriers 
by assessing 41  KLK14 gene region SNPs ( ± 10 kb) in our 
large prostate cancer case series and male controls. 
 Results 
 We have previously shown that  KLK14 mRNA is widely 
expressed in prostate cell lines, unlike  KLK2 and  KLK3 , which 
are only expressed in androgen-responsive cells (Lawrence 
et al. , 2010 ). Using Western blots, we observed that KLK14 
protein (Figure  1 ) has the same expression profi le. KLK14 
is expressed not only in LNCaP, 22Rv1 and MDA-PCa-2b 
cells, which are all androgen responsive, but also in PC3 and 
DU145 cells, albeit at lower levels, which lack the AR. 
 The broad expression profi le of KLK14 implies that it 
does not depend on AR signalling. To confi rm this obser-
vation, increasing concentrations of the synthetic androgen 
R1881 were added to LNCaP cells, a model of androgen-
dependent prostate cancer that resembles our patient cohort. 
Surprisingly,  KLK14 mRNA expression was signifi cantly 
down-regulated by treatment with 1 and 10 n m R1881 (Figure 
 2 A). A time course of R1881 treatment showed that  KLK14 
mRNA was signifi cantly down-regulated at 24 h (Figure 2B); 
however, the decrease in KLK14 protein was not apparent 
until 7 days of R1881 treatment (Figure 2C). To confi rm these 
changes, we investigated whether decreasing AR activity has 
 Figure 1  KLK14 is ubiquitously expressed in prostate cancer 
cells. 
 Western blots of KLK14 expression in LNCaP, 22Rv1, PC-3, DU145 
and MDA-PCa-2b prostate cell lines. KLK14 was detected as an 
approximately 22-kDa band. GAPDH was used as a loading control. 
Representative data from two experiments are shown. 
the opposite effect on  KLK14 expression. LNCaP cells were 
deprived of hormones by being cultured in medium contain-
ing charcoal-stripped serum (CSS). After 4 days, there was 
an increase in both  KLK14 mRNA (Figure 2D) and protein 
(Figure 2E) levels. As expected, there was also a decrease in 
AR protein in hormone-deprived LNCaP cells (Figure 2E). 
When AR activity was blocked pharmacologically, using 
the AR antagonist bicalutamide,  KLK14 expression was 
restored compared with R1881 treatment alone (Figure 2F). 
Furthermore,  KLK14 expression was actually stimulated with 
100  μ m bicalutamide. These changes are specifi c to AR activ-
ity because siRNA knockdown of the AR also rescues  KLK14 
expression (Figure 2G). These observations show that  KLK14 
is moderately, but signifi cantly, down-regulated by AR sig-
nalling, and is therefore differentially regulated compared 
with other prostatic KLKs. 
 Given that  KLK14 is consistently expressed in prostate 
cancer cells and signifi cantly upregulated in a hormone-
deprived milieu (CSS) or on anti-androgen treatment (bicalu-
tamide), and may play a role in prognosis, we investigated 
whether SNPs within the  KLK14 gene are associated with 
the occurrence and aggressiveness of prostate cancer. Six 
SNPs were found to be non-polymorphic in our sample group 
(Table  1 ). Results of analyses of the remaining 35  KLK14 
SNPs and risk of prostate cancer are displayed in Table  2 . No 
 KLK14 SNPs were statistically signifi cantly associated with 
prostate cancer risk or tumour aggressiveness after Bonferroni 
correction ( p ≤ 0.0014). SNP rs66613646 was associated with 
a modest increased risk of prostate cancer at the  p ≤ 0.05 
level [odds ratio (OR) 1.19, 95 % confi dence interval (CI) 
1.03 – 1.38,  p trend = 0.022]; however, there was no association 
with risk for tagSNP rs867192 (OR 1.05, 95 % CI 0.91 – 1.22, 
 p trend = 0.521; Table 1), found by analysis of our control dataset 
to be in high linkage disequilibrium (LD) with rs66613646 
(r 2 = 0.79; data not shown). 
 In relation to the possible role of  KLK14 SNPs in tumour 
aggressiveness, three SNPs displayed  p -values of  ≤ 0.05 
when Gleason scores  < 7 were compared with  ≥ 7 (Table  3 ). 
Rs17728459 located approximately 9 kb upstream of  KLK14 
was associated with a protective effect, with an OR of 0.33 
(95 % CI 0.15 – 0.73,  p trend = 0.006). A similar result was also 
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 Figure 2  KLK14 is down-regulated by androgens. 
 (A)  KLK14 expression in LNCaP cells treated with 0 – 10 n m R1881 for 24 h. Data are from qPCR analysis and expressed as average fold 
changes vs. the ethanol control (n = 3, asterisks indicate signifi cant difference in the fold change relative to 0 n m ). (B) Relative  KLK14 expres-
sion in LNCaP cells treated with 1 n m R1881 for up to 24 h as measured using qPCR. Data represent average fold changes vs. the correspond-
ing ethanol control for each time point (n = 2, asterisks indicate signifi cant differences between R1881 and the control at each time point). (C) 
Western blots of KLK14 protein expression in LNCaP cells treated with 0 – 10 n m R1881 for 1 day or 1 n m R1181 for 3 and 7 days. DU145 
cells (DU), which express lower levels of KLK14, were used as control. GAPDH was used to confi rm equal protein loading. Representative 
data from two (7 days) or three (1 and 3 days) separate experiments are shown. (D) qPCR data of  KLK14 expression in LNCaP cells cultured 
in medium with CSS for up to 10 days. Results represent average fold changes compared with day 0 (n = 3, asterisks indicate signifi cant differ-
ence in fold change relative to day 0). (E) Western blots of KLK14 and GAPDH expression in hormone-deprived LNCaP cells. Representative 
data from two independent experiments are shown. (F)  KLK14 expression in LNCaP cells treated with 1 n m R1881 and 0 – 100  μ m bicalutamide 
(BIC). Relative fold changes vs. R1881 alone were measured using qPCR (n = 3, asterisks indicate signifi cant difference in fold change relative 
to R1881 alone). LNCaP cells treated with and without 1 n m R1881 were also compared. (G) QPCR data of AR (white bars) and  KLK14 (grey 
bars) expression in LNCaP cells transfected with control or AR-specifi c siRNA and treated for 48 h with 1 n m R1881. Data are normalised to 
the mock transfection control (n = 3, general linear model, asterisks indicate signifi cant difference between control and AR-specifi c siRNA). For 
all experiments,    p < 0.05,    p < 0.01,    p < 0.001. 
seen when  ‘ extreme ’ Gleason scores were compared ( ≤ 6 
vs.  ≥ 8, Table  4 ), although sample numbers were substantially 
decreased and the CI overlapped unity. Rs4802765, located 
around 2 kb upstream of  KLK14 , displayed a borderline 
association with increased risk of tumour aggressiveness (OR 
1.31, 95 % CI 1.00 – 1.72,  p trend = 0.050); however, this effect 
was not refl ected in the Gleason score  ≤ 6 vs.  ≥ 8 analysis, 
despite the high minor allele frequency of 0.33. Rs35287116 
displayed an association with increased tumour aggressive-
ness (OR 1.28, 95 % CI 1.06 – 1.56,  p trend = 0.012), which was 
similarly refl ected when analyses were restricted to Gleason 
score  ≤ 6 vs.  ≥ 8 (Table 4; OR 1.38, 95 % CI 1.03 – 1.85, 
 p trend = 0.030). Studies in our control set revealed rs35287116, 
encoding a glutamine to arginine amino acid substitution at 
position 33 in the signal peptide region of KLK14 (Clements 
et al. , 2004 ), was correlated with rs10500304 (r 2 = 0.87), 
and this SNP showed comparable, although not signifi cant, 
results (OR 1.18, 95 % CI 0.95 – 1.46,  p trend = 0.130). In addi-
tion, SNP rs73051038 exhibited an association with increased 
tumour aggressiveness only when analyses were restricted 
to  ‘ extreme ’ Gleason scores, with OR for Gleason score  ≤ 6 
vs.  ≥ 8 of 1.94 (95 % CI 1.10 – 3.40,  p trend = 0.021), in the same 
 Table 1  Rs IDs found to be very rare or non-polymorphic in this 
study. 
Rs ID Ref. allele Controls (n) Cases (n) Samples 
detected (n)
rs1880416 C 1213 1228 0
rs73596505 C 1266 1236 0
rs73596515 G 1272 1229 0
rs2569494 G 1215 1228 1
rs2569495 T 1215 1228 0
rs2691268 G 1272 1229 0
 ID, identifi er; Ref., reference; n, number. 
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direction as results for Gleason score  < 7 vs.  ≥ 7 (OR 1.38, 
95 % CI 0.91 – 2.07,  p trend = 0.126). 
 Discussion 
 Since  KLK14 was fi rst cloned in 2001, the prostate has been 
known to be a prominent site of  KLK14 gene expression 
(Hooper et al. , 2001 ; Yousef et al. , 2001 ). Yet, relatively lit-
tle is known about the expression profi le and transcriptional 
regulation of  KLK14 in the prostate. In this study, we showed 
that  KLK14 is more broadly expressed across androgen-
responsive and -insensitive cell lines and is down-regulated 
by AR signalling. 
 Considering that prostatic KLKs such as  KLK2 and  KLK3 
are classical AR-activated genes (Lawrence et al. , 2010 ), 
the observation that androgens suppress  KLK14 expression 
was unexpected. The down-regulation of  KLK14 was mod-
est, but consistent, with a 40 – 75 % decrease depending on the 
experiment. There was a much more rapid decrease in  KLK14 
mRNA compared with protein levels. This may be due to the 
relative instability of  KLK14 mRNA, which has a half-life of  < 6 
h (M. Lawrence, unpublished observations). Nevertheless, as 
has also been noted in studies that measured secreted KLK14 
levels with ELISAs (Paliouras and Diamandis , 2007, 2008a ), 
changes in KLK14 mRNA and protein levels are correlated. 
Moreover, the changes we observed are specifi c because 
 KLK14 levels increase with extended hormone deprivation, 
bicalutamide treatment and AR knockdown. The modula-
tion, but not complete repression, of  KLK14 expression is also 
consistent with its ubiquitous expression among prostate cancer 
cell lines. Intriguingly, these results may be tissue specifi c; pre-
vious studies have shown that  KLK14 is up-regulated by andro-
gens in a range of breast and ovarian cancer cell lines (Borgono 
et al. , 2003 ; Yousef et al. , 2003a ; Paliouras and Diamandis , 
2007, 2008b ). Therefore, whether  KLK14 is activated or 
repressed by androgens may depend on crosstalk between the 
AR and other signalling pathways in different cell types. 
 Table 2  Association of  KLK14 SNPs and prostate cancer risk. 
 KLK14 SNP Ref. allele Alt. allele Controls (n) Cases (n) OR (95 % CI)  p trend 
rs73596564 A G 1072 1070 1.39 (0.48 – 4.02) 0.547
rs17728459 C T 1094 1087 0.91 (0.55 – 1.51) 0.712
rs73596556 C T 1210 1224 1.83 (0.61 – 5.48) 0.283
rs2691271 C G 1255 1225 0.87 (0.75 – 1.01) 0.060
rs12984853 G A 1262 1233 0.99 (0.88 – 1.11) 0.890
rs34974522 G A 1204 1210 0.93 (0.83 – 1.04) 0.201
rs2691270 A G 1258 1186 1.06 (0.95 – 1.19) 0.288
rs2569497 T C 1214 1225 0.93 (0.81 – 1.07) 0.291
rs34368430 G A 1214 1227 1.10 (0.97 – 1.24) 0.141
rs1880417 A G 1272 1229 2.30 (0.21 – 25.46) 0.496
rs4802765 T C 1265 1220 0.87 (0.75 – 1.02) 0.083
rs7259389 C T 1249 1171 0.98 (0.84 – 1.15) 0.833
rs73596529 C T 1212 1226 0.96 (0.82 – 1.14) 0.665
rs7260199 C T 1205 1214 0.96 (0.85 – 1.08) 0.481
rs12609392 G A 1206 1212 0.99 (0.88 – 1.11) 0.869
rs73051038 G C 1266 1240 0.98 (0.79 – 1.22) 0.863
rs2072689 G A 1309 1001 1.08 (0.96 – 1.21) 0.199
rs2235100 A G 1296   994 1.01 (0.87 – 1.17) 0.934
rs2691244 A G 1307   997 1.10 (0.98 – 1.25) 0.121
rs62114145 G A 1252 1184 1.06 (0.91 – 1.23) 0.450
rs62114144 G A 1202 1211 1.14 (0.98 – 1.33) 0.078
rs35287116 T C 1264 1238 1.06 (0.94 – 1.18) 0.354
rs2569491 G A 1254 1172 1.07 (0.94 – 1.21) 0.313
rs2569490 C T 1183 1193 1.43 (0.61 – 3.36) 0.414
rs10500304 A C 1296   995 1.08 (0.96 – 1.22) 0.218
rs10445581 G C 1315 1003 1.05 (0.92 – 1.19) 0.495
rs867192 C A 1291   977 1.05 (0.91 – 1.22) 0.521
rs11671942 C T 1327 1002 0.96 (0.79 – 1.16) 0.680
rs11671800 C A 1326 1000 1.06 (0.91 – 1.24) 0.441
 rs66613646  G  T  1195  1194  1.19 (1.03 – 1.38)  0.022 
rs2569487 G A 1252 1183 0.93 (0.82 – 1.05) 0.251
rs2569485 T C 1261 1237 1.02 (0.91 – 1.14) 0.708
rs7253072 C T 1258 1185 1.06 (0.88 – 1.28) 0.520
rs7253169 G A 1256 1227 1.02 (0.85 – 1.22) 0.831
rs2691215 A T 1071 1068 0.97 (0.86 – 1.10) 0.632
 SNP, single nucleotide polymorphism; Ref., reference; Alt., alternate; n, number; OR, odds ratio; CI, confi dence interval. 
Bold font indicates  SNP displaying a  p -value  ≤ 0.05. 
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 The repressive actions of the AR are well recognised but 
poorly understood. Studies have noted that slightly fewer 
genes are repressed by androgens than stimulated (Clegg 
et al. , 2002 ; Bolton et al. , 2007 ; Prescott et al. , 2007 ). Like 
 KLK14 , most of these genes are moderately down-regulated 
rather than completely repressed (Kojima et al. , 2006 ; Prescott 
et al. , 2007 ). One potential mechanism is that AR actively 
inhibits target gene expression by recruiting co-repressor pro-
teins such as NCoR and SMRT. This is unlikely for  KLK14 
because its expression is rescued by bicalutamide, which 
maintains the ability of the AR to interact with co-repressor 
and bind to DNA (Hodgson et al. , 2007 ; Prescott et al. , 2007 ). 
The AR also down-regulates gene expression without bind-
ing to target promoters. It can compete for limited pools of 
co-activators or form inhibitory interactions with other tran-
scription factors such as NF κ B, Sp1, AP-1, cJun and ATF2 
 Table 3  Association of  KLK14 SNPs and prostate tumour 
aggressiveness (Gleason score  < 7 vs.  ≥ 7). 
 KLK14 SNP GS  < 7 (n) GS  ≥ 7 (n) OR (95 % CI)  p trend 
rs73596564 274 685 2.02 (0.22 – 18.22) 0.533
 rs17728459  264  704  0.33 (0.15 – 0.73)  0.006 
rs73596556 a 310 785  – 1.000
rs2691271 316 794 1.00 (0.78 – 1.28) 0.989
rs12984853 312 801 0.95 (0.79 – 1.15) 0.621
rs34974522 301 781 0.98 (0.81 – 1.19) 0.840
rs2691270 300 763 1.18 (0.97 – 1.43) 0.100
rs2569497 310 786 0.88 (0.70 – 1.11) 0.280
rs34368430 310 788 1.00 (0.81 – 1.23) 0.967
rs1880417 319 794 0.50 (0.03 – 8.06) 0.626
 rs4802765  314  791  1.31 (1.00 – 1.72)  0.050 
rs7259389 294 756 1.14 (0.87 – 1.50) 0.343
rs73596529 310 787 1.09 (0.82 – 1.46) 0.540
rs7260199 302 786 1.04 (0.85 – 1.28) 0.676
rs12609392 300 785 1.01 (0.84 – 1.22) 0.905
rs73051038 313 807 1.38 (0.91 – 2.07) 0.126
rs2072689 259 610 0.84 (0.69 – 1.03) 0.099
rs2235100 258 602 1.14 (0.87 – 1.49) 0.359
rs2691244 259 606 1.07 (0.87 – 1.33) 0.522
rs62114145 300 760 0.85 (0.66 – 1.09) 0.192
rs62114144 301 783 0.87 (0.68 – 1.11) 0.255
 rs35287116  312  806  1.28 (1.06 – 1.56)  0.012 
rs2569491 295 754 0.98 (0.79 – 1.21) 0.845
rs2569490 a 296 771  – 1.000
rs10500304 258 603 1.18 (0.95 – 1.46) 0.130
rs10445581 259 611 1.16 (0.92 – 1.45) 0.207
rs867192 252 591 1.17 (0.90 – 1.53) 0.249
rs11671942 260 609 1.08 (0.76 – 1.52) 0.676
rs11671800 260 606 1.10 (0.84 – 1.43) 0.509
rs66613646 306 765 1.14 (0.89 – 1.45) 0.302
rs2569487 299 762 0.89 (0.72 – 1.09) 0.265
rs2569485 313 805 1.03 (0.85 – 1.24) 0.768
rs7253072 299 762 0.87 (0.64 – 1.18) 0.368
rs7253169 311 797 1.13 (0.83 – 1.55) 0.437
rs2691215 274 685 1.04 (0.85 – 1.28) 0.716
 SNP, single nucleotide polymorphism; GS, Gleason score; n, number; 
OR, odds ratio; CI, confi dence interval. 
Bold font indicates SNPs displaying a  p -value  ≤ 0.05. 
 
a
 SNP too infrequent in these groups to calculate OR (95 % CI). 
 Table 4  Association of  KLK14 SNPs and prostate tumour 
aggressiveness (Gleason score  ≤ 6 vs.  ≥ 8). 
 KLK14 SNP GS  ≤ 6 (n) GS  ≥ 8 (n) OR (95 % CI)  p trend 
rs73596564 a 274 128  – 1.000
rs17728459 264 176 0.15 (0.02 – 1.15) 0.068
rs73596556 b 310 151  – 
rs2691271 316 158 0.88 (0.61 – 1.28) 0.506
rs12984853 312 160 1.05 (0.79 – 1.41) 0.733
rs34974522 301 151 1.06 (0.79 – 1.42) 0.720
rs2691270 300 162 1.14 (0.86 – 1.51) 0.367
rs2569497 310 151 0.85 (0.59 – 1.21) 0.366
rs34368430 310 152 1.10 (0.80 – 1.51) 0.571
rs1880417 319 158  – 1.000
rs4802765 a 314 157 1.18 (0.80 – 1.74) 0.401
rs7259389 294 161 1.16 (0.79 – 1.72) 0.447
rs73596529 310 151 1.22 (0.81 – 1.83) 0.349
rs7260199 302 157 0.77 (0.56 – 1.05) 0.095
rs12609392 300 157 1.27 (0.95 – 1.68) 0.103
 rs73051038  313  163  1.94 (1.10 – 3.40)  0.021 
rs2072689 259 145 0.95 (0.71 – 1.27) 0.713
rs2235100 258 145 1.30 (0.89 – 1.88) 0.173
rs2691244 259 144 1.11 (0.82 – 1.51) 0.504
rs62114145 300 161 0.89 (0.62 – 1.29) 0.547
rs62114144 301 157 0.84 (0.58 – 1.22) 0.371
 rs35287116  312  162  1.38 (1.03 – 1.85)  0.030 
rs2569491 295 162 0.96 (0.70 – 1.32) 0.798
rs2569490 a 296 154  – 1.000
rs10500304 258 146 1.24 (0.91 – 1.68) 0.169
rs10445581 259 145 1.19 (0.86 – 1.64) 0.294
rs867192 252 142 1.18 (0.82 – 1.72) 0.377
rs11671942 260 145 1.10 (0.67 – 1.81) 0.697
rs11671800 260 145 1.10 (0.75 – 1.61) 0.632
rs66613646 306 147 1.11 (0.76 – 1.61) 0.591
rs2569487 299 162 0.87 (0.63 – 1.19) 0.376
rs2569485 313 162 1.08 (0.81 – 1.44) 0.583
rs7253072 299 162 0.92 (0.59 – 1.45) 0.725
rs7253169 311 163 1.26 (0.80 – 1.98) 0.312
rs2691215 274 128 1.11 (0.80 – 1.53) 0.538
 SNP, single nucleotide polymorphism; GS, Gleason score; n, num-
ber; OR, odds ratio; CI, confi dence interval. 
Bold font indicates SNPs displaying a  p -value 0.05. 
 
a
 SNP too infrequent in these groups to calculate OR (95 % CI). 
 
b
 Rare allele was not detected in either group. 
(Grosse et al. , 2012 ). Therefore, the  KLK14 promoter should 
be further characterised to help determine the mechanism of 
AR-mediated repression. 
 The differential androgen regulation of  KLK14 compared 
with other prostatic KLKs has important implications for their 
relative expression profi les in prostate cancer. AR-activated 
genes such as  KLK2 and  KLK3 are generally down-regulated 
as the primary tumour de-differentiates and are then further 
reduced in metastases (Clegg et al. , 2002 ; Bolton et al. , 2007 ; 
Prescott et al. , 2007 ). In patients that undergo androgen depri-
vation therapy, AR activated genes are initially down-regu-
lated, but are then re-expressed in castrate-resistant disease 
(Holzbeierlein et al. , 2004 ). Although  KLK3 expression gen-
erally follows these trends, it is highly heterogeneous after 
hormone deprivation therapy as tumours proceed towards 
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castration resistance (Mostaghel et al. , 2007 ). This variability 
may be due to the different ways that prostate cancer cells 
adapt to castrate androgen levels. Although the effect of hor-
mone ablation on  KLK14 expression has not yet been reported, 
other genes that are repressed by androgens, such as  IGFBP3 
and  relaxin , are initially up-regulated by hormone deprivation 
therapy, but then decrease in castrate-resistant prostate cancer 
(Kojima et al. , 2006 ; Thompson et al. , 2006 ). This suggests 
that  KLK3 and  KLK14 may have opposite expression profi les. 
If this is the case, the ratio of  KLK3 to  KLK14 expression may 
be a useful measure of AR activity that overcomes some of 
the variability between patients. Therefore, further analysis 
of the relative expression profi les of  KLK3 ,  KLK14 and other 
prostatic KLKs is warranted. 
 In parallel to our investigation of the androgen regula-
tion of  KLK14 expression, we performed a comprehensive 
investigation of the role of common genetic variations in the 
 KLK14 gene in prostate cancer risk and/or tumour aggres-
siveness by assessing the majority of  KLK14 SNPs that have 
not been covered by previously performed genome-wide 
association (GWA) studies. Our study of over 1200 cases and 
1300 male controls identifi ed no SNPs to be associated with 
prostate cancer predisposition, but revealed several  KLK14 
SNPs to be potentially associated with tumour aggressive-
ness. To the best of our knowledge, only one other study has 
specifi cally examined the role of  KLK14 SNPs in prostate 
cancer aside from genome-wide investigations. Analogous 
to our fi ndings, the study by Klein et al.  (2010) found 
none of the  KLK14 SNPs assessed (including rs2569491, 
rs35287116, rs7260199, rs7259389 and rs73596529 exam-
ined in our study) to be associated with prostate cancer risk 
in the Cancer Prostate in Sweden (CAPS) 1 sample set of 
over 1400 cases and 700 controls. The study of Klein et 
al. did not assess the relation of  KLK14 SNPs with tumour 
aggressiveness. 
 In our study of approximately 1200 cases, two SNPs 
upstream of  KLK14 were found to be associated with tumour 
aggressiveness, rs17728459 with decreased aggressiveness 
and rs4802765 with more aggressive tumours. Neither were 
located in known or predicted hormone response elements 
(Sandelin and Wasserman , 2005 ; Kennedy et al. , 2010 ), 
although preliminary bioinformatic analysis of the poten-
tial effects of rs4802765 T > C on transcription factor bind-
ing sites (Grabe , 2000 ) predicted that the presence of the C 
allele introduces two Sp1 sites and an NF-1 site. Interestingly, 
Sp1 regulates the expression of the  AR and  KLK3 genes, and 
Sp1 expression has been found to be elevated in prostate can-
cer and associated with prognosis (Sankpal et al. , 2011 ). In 
addition, a GWAS-identifi ed prostate cancer-associated SNP 
near the  NKX3.1 gene (Eeles et al. , 2009 ) has recently been 
shown to alter the binding of Sp1 (Akamatsu et al. , 2010 ). 
We also identifi ed SNP rs35287116 in the coding region of 
 KLK14 to be associated with increased tumour aggressive-
ness. Rs35287116 encodes the non-synonymous substitu-
tion p.Gln33Arg in the signal peptide region (Clements 
et al. , 2004 ), but is not predicted to alter cleavage of the signal 
peptide by SignalP 3.0 (Bendtsen et al. , 2004 ) or PSORT II 
(Nakai and Horton , 1999 ) and is calculated to be tolerated 
by the bioinformatic algorithms SIFT (Ng and Henikoff , 
2001 ) and PolyPhen-2 (Adzhubei et al. , 2010 ). However, 
ESEFinder (Smith et al. , 2006 ) predicts that rs35287116 may 
affect an exonic splicing enhancer site and hence alter splic-
ing of  KLK14 . 
 Although the functional role of KLK14 in prostate can-
cer has not been investigated, the substrates that have been 
identifi ed in biochemical studies could explain the asso-
ciation between  KLK14 SNPs and tumour aggressiveness. 
KLK14 is normally secreted into seminal plasma (Borgono 
et al. , 2007 ; Emami et al. , 2008 ), but the breakdown of 
glandular architecture in prostate cancer likely leads to the 
accumulation of KLK14 in the tumour microenvironment. 
KLK14 may directly promote the migration and invasion 
of tumour cells by activating proteinase activated recep-
tor 2 signalling (Oikonomopoulou et al. , 2006 ; Stefansson 
et al. , 2008 ; Gratio et al. , 2011 ); degrading extracellular 
matrix proteins such as fi bronectin, laminin and collagen I to 
IV (Borgono et al. , 2007 ; Rajapakse and Takahashi , 2007 ); 
and activating enzyme cascades with KLK1-3, KLK5 and 
KLK11 (Brattsand et al. , 2005 ; Yoon et al. , 2007 ; Emami 
and Diamandis , 2010 ). KLK14 also activates latent trans-
forming growth factor  β 1 (Emami and Diamandis , 2010 ) and 
degrades insulin-like growth factor binding proteins 2 and 3 
(Borgono et al. , 2007 ), suggesting it affects the growth and 
differentiation of prostate cancer cells. Ultimately, however, 
the actions of KLK14 in the tumour microenvironment will 
also depend on the levels of other proteases that activate it, 
as well as serpins and metal ions that inhibit KLK14 enzyme 
activity. 
 To date, there has been little success in attempts to delin-
eate, and then validate, the contribution of SNPs to prostate 
tumour aggressiveness (Duggan et al. , 2007 ; Kader et al. , 
2009 ; Witte , 2009 ; Lubahn et al. , 2010 ; Fitzgerald et al. , 
2011 ; Lin et al. , 2011 ). There are several possible reasons for 
this (reviewed in Oon et al. , 2011 ), such as the fact that one 
prostate can have multiple tumour foci that display different 
Gleason scores, and it is well known that there is much hetero-
geneity between tumours that are graded Gleason score 7. We 
attempted to circumvent some issues involving tumours with 
Gleason score 7 by restricting analyses to those patients with 
the more  ‘ extreme ’ Gleason scores of  ≤ 6 and  ≥ 8. Although 
this depleted our sample set dramatically, several SNPs 
remain candidates for further investigation in larger sample 
sets. Unfortunately, long-term follow-up data were not avail-
able for our prostate cancer cases, so we could not investigate 
the role of  KLK14 SNPs in prognosis at this time; however, 
this will be an important analysis in the future. 
 In summary, we have demonstrated that unlike other 
prostate-expressed  KLK genes that are strictly androgen 
responsive,  KLK14 is more broadly expressed and inversely 
androgen regulated, increased by anti-androgens and in an 
androgen-deprived milieu. This suggests that KLK14 expres-
sion is maintained throughout prostate cancer, including the 
initial stages of hormone deprivation, with subsequent pro-
teolytic effects in the tumour microenvironment that pro-
mote tumour progression. In addition, our well-sized study 
suggests a contribution of SNPs in the  KLK14 gene to the 
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development of more aggressive prostate cancer, an interest-
ing fi nding considering previous reports that KLK14 expres-
sion is a possible prognostic factor for tumour characteristics 
and progression-free survival. Validation of these results in 
much larger sample sets such as those available from the 
PRACTICAL prostate cancer consortium would highlight 
 KLK14 SNPs as a possible prognostic marker to identify 
patients that may benefi t from more immediate and proactive 
treatment of their disease. 
 Materials and methods 
 KLK14 expression and androgen regulatory studies 
 Cell culture and androgen treatments  LNCaP, 22Rv1, PC3, 
DU145 and MDA-PCa-2b prostate cancer cell lines were acquired 
from the American Type Culture Collection (Manassas, VA, USA). 
All cells were grown in RPMI 1640 medium (Invitrogen, Mount 
Waverly, Australia) with 10 % foetal calf serum (FCS, Invitrogen), 50 
U/ml penicillin G and 50  μ g/ml streptomycin (Invitrogen), except for 
MDA-PCa-2b cells, which were cultured in BRFF-HPC1 medium 
(AthenaES, Baltimore, MD, USA) with 20 % FCS and antibiotics. 
LNCaP cells were cultured in phenol red-free RPMI 1640 with 10 % 
CSS for 72 h before androgen treatments. Cells were then treated 
with 0.01 – 10 n m R1881 (Perkin Elmer, Boston, MA, USA) or etha-
nol vehicle control for 24 h, unless otherwise stated. For hormone 
deprivation experiments, LNCaP cells were cultured in medium con-
taining CSS for up to 10 days with medium changes after 4 and 7 
days. For bicalutamide treatments, cells were pre-treated for 2 h with 
0 – 100  μ m bicalutamide (AstraZeneca, Brisbane, QLD, Australia) 
and then cultured for a further 24 h with 1 n m R1881 and bicalu-
tamide. AR knockdown with siRNA was performed as previously 
described (Jia et al. , 2006, 2008 ). LNCaP cells were transfected with 
an AR-specifi c or scrambled siRNA for 48 h using Oligofectamine 
(Invitrogen) and then treated for 48 h with 1 n m R1881. 
 RNA extractions and quantitative RT-PCR  Total RNA was 
extracted using TRIzol and then treated with DNase I (Invitrogen). 
SuperScript III reverse transcriptase was used to synthesise cDNA 
(Invitrogen). Quantitative PCR (qPCR) was performed with ABI 
PRISM 7000, 7300 and 7900 thermocyclers and SYBR Green PCR 
Master Mix (Applied Biosystems, Scoresby, Australia).  KLK14 , 
 GAPDH and  18S primer sequences have previously been reported 
(Lawrence et al. , 2010 ). The comparative C T ( Δ Δ C T ) method was used 
to calculate relative gene expression compared with control samples. 
 Protein extractions and Western blotting  Cells were ly-
sed in buffer containing 10 m m Tris (pH 8.0), 150 m m NaCl, 5 
m m EDTA, 1 % Triton X-100 and 1 × complete protease inhibi-
tor cocktail (Roche, West End, QLD, Australia), and total pro-
tein concentrations were measured using a Bicinchoninic Assay 
Kit (Pierce, Progen, Darra, QLD, Australia). Forty micrograms of 
each sample was separated using 14 % sodium dodecyl sulphate-
polyacrylamide gels. Membranes were probed with either a rab-
bit anti-KLK14 catalytic domain antibody [a gift from Preston 
Alexander, TriplePoint Biologics (Forest Grove, OR), and also avail-
able from Abcam, Cambridge, MA, USA] or a rabbit anti-GAPDH 
antibody (Abcam) diluted in Odyssey buffer (LI-COR Biosciences, 
Millennium Science, Surrey Hills, NSW, Australia). The blots were 
then incubated with a goat-anti-rabbit-680 (Invitrogen) fl uorescent 
secondary antibody and imaged using a LI-COR Odyssey scanner. 
Odyssey software was used to adjust the brightness, contrast and in-
tensity of images. 
 Analysis of  KLK14 SNPs in prostate cancer cases and 
controls 
 Study subjects  Study subjects have been described elsewhere 
(Baade et al. , 2010 ; Lose et al. , 2011 ). Briefl y, from 2004 onwards, 
1349 histopathologically confi rmed prostate cancer cases were 
recruited through private and public urologists in Queensland, 
Australia, through three prostate cancer studies or resources: the 
Retrospective Queensland Study (n = 154; Lai et al. , 2007 ), the 
Prostate Cancer Supportive Care and Patient Outcomes Project 
(ProsCan, n = 857; Baade et al. , 2010 ) and from the Australian Prostate 
Cancer BioResource (APCB, n = 338; http://www.apccbioresource.
org.au/index.html). Men presented to urologists with lower urinary 
tract symptoms and/or abnormal serum PSA, and 72 % of cases pos-
sessed prostate tumours of Gleason score 7 or above. Cases ranged 
in age at diagnosis from 36 to 88 years (median 63 years). Male con-
trols (n = 1405) with no self-reported personal history of prostate can-
cer were randomly selected from the Australian Electoral Roll and 
age-matched (in 5-year groups) and post-code matched to cases 
(n = 569), or recruited through the Australian Red Cross Blood 
Services in Brisbane (n = 836). Controls were not screened for PSA 
levels and analyses excluded 38 controls with age at interview  < 36 
years (the age of the youngest case); included controls ranged in age 
at interview from 36 to 89 years of age (median 62 years). All partici-
pants had self-reported Caucasian ethnicity and gave written informed 
consent. The study protocol was approved by the Human Research 
Ethics Committees of the Queensland University of Technology, 
Queensland Institute of Medical Research, the Mater Hospital (for 
Brisbane Private Hospital), the Royal Brisbane Hospital, Princess 
Alexandra Hospital and the Cancer Council Queensland. 
 SNP selection and genotyping  The  KLK14 gene region used 
for SNP selection was chr19:56262966..56289314 (hg18), which 
encompasses the  KLK14 gene  ± 10 kb. All SNPs in this region were 
extracted from National Center for Biotechnology Information 
(NCBI) dbSNP build 130 (Sherry et al. , 2001 ), CHIP SNPper (Riva 
and Kohane , 2004 ) and the  ‘ ParSNPs ’ database (Goard et al. , 2007 ) 
and duplicates were removed. SNPs not classifi ed as validated were 
removed, and validated SNPs were further investigated for occur-
rence in Caucasians using SPSmart (Amigo et al. , 2008 ) and 1000 
Genomes (2010). Additional SNPs excluded from investigation 
included all SNPs on the Illumina 550K, 610K and Omni1 genome-
wide genotyping chips and SNPs assessed in the Cancer Genetic 
Markers of Susceptibility (CGEMS) project (Yeager et al. , 2007 ), 
unless there was evidence of association with prostate cancer by 
CGEMS ( p < 0.05). SNPs in high LD (r 2 ≥ 0.80) with these excluded 
Illumina and CGEMS SNPs were also removed, determined by the 
SNP Annotation and Proxy Search program (SNAP) version 2.1 
(Johnson et al. , 2008 ) using HapMap release 22 (1000 Genomes data 
was not available at the time of initiation of this study). We then pri-
oritised for genotyping all independent SNPs (r 2 < 0.80) according to 
SNAP using HapMap release 22 data (n = 42). As part of a previous 
study, we had also genotyped eight  KLK14 tagSNPs (selected using 
HapMap data release 24/phase II, Nov 2008, NCBI build 36, dbSNP 
b126, using the Tagger program within Haploview v4.1; Barrett 
et al. , 2005 ). 
 SNPs were genotyped using iPLEX Gold assays on the Sequenom 
MassARRAY platform (Sequenom, San Diego, CA, USA), as 
described previously (Lose et al. , 2010 ). There were four negative 
(H 2 O) controls per 384-well plate, and quality control parameters 
included genotype call rates  > 95 % , a combination of cases and con-
trols on each plate, inclusion of 20 duplicate samples per 384-well 
plate ( > 5 % of samples) with  ≥ 98 % concordance between duplicates 
and Hardy-Weinberg equilibrium  p -values  > 0.05. Of a total of 50 
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 KLK14 SNPs selected for investigation, six could not be designed 
for Sequenom assays, and after application of quality control param-
eters, 41 SNPs were successfully genotyped. 
 Statistical methods 
 Gene expression data were analysed using Predictive Analytics 
Software (PASW) Statistics version 17.0.2 (SPSS Inc., Chicago, IL, 
USA) and GraphPad Prism. The signifi cance of fold changes relative 
to the reference group was assessed by one-sample t-test. Differences 
of the fold changes between groups were assessed using one-way 
ANOVA, and when there was evidence of variance heterogeneity 
the Brown-Forsythe robust test (Brown and Forsythe , 1974 ) was 
used. General linear models were used to compare the fold changes 
relative to mock R1881 between the control and AR siRNA groups 
(Figure 2G). All error bars represent the standard error of the mean of 
biological replicates performed on separate occasions.  p -Values are 
indicated by   for  p < 0.05,   for  p < 0.01, and   for  p < 0.001. 
 PASW Statistics version 17.0.2 (SPSS Inc.) was used for genetic 
analyses. Genotype and allele frequencies were calculated for the 
patient and control groups. Comparisons of allele and genotype dis-
tribution and their association with prostate cancer susceptibility and 
clinical data were analysed under a linear model using logistic regres-
sion analysis and all analyses were adjusted for age (as a continuous 
variable). Prostate cancer cases with tumour Gleason scores  ≥ 7 were 
classifi ed as aggressive. Analyses were also performed comparing 
 ‘ extreme ’ Gleason categories,  ≤ 6 (maximum number of cases = 334) 
vs.  ≥ 8 (maximum cases = 176). 
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